| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Aptorum Group Limited (NASDAQ:APM) shares declined 33.18% to $2.84 in after-hours trading session on Friday following Thursday’s explosive 234.65% rally. According to Benzinga Pro data, Aptorum closed the regular trading session at $4.25.
Check out the current price of APM stock here.
DiamiR Biosciences Corp., Aptorum’s merger partner, secured Clinical Laboratory Evaluation Program approval from New York State Department of Health for its APOE Genotyping test. The CLIA-certified laboratory can now offer cognitive decline risk assessment testing.
“This milestone expands access to an important tool that can help inform risk assessment, clinical trial enrollment, and personalized care strategies,” said Alidad Mireskandari, CEO of DiamiR Biosciences.
The companies agreed to an all-stock merger in July, with DiamiR becoming a wholly owned subsidiary. The transaction expects fourth quarter closing while maintaining Nasdaq listing.
Friday’s session generated 168.16 million shares in trading volume, sharply above the 6.87 million average. The stock trades within a 52-week range of $0.48 to $7.49 and holds a market cap of $30.36 million. Aptorum regained compliance with Nasdaq's minimum bid price requirement earlier in August.
Read Next:
REDPIXEL.PL from Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Posted In: APM
